Lumacaftor

1. Lumacaftor - CAS 936727-05-8 Catalog number: B0084- 079818 Lumacaftor is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF). Lumacaftor may act to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, the defective cell membrane protein responsible for the progression of CF. Lumacaftor defects in the CFTR protein affect the transport of chloride and other ions across cells, and lead to the accumulation of thick, sticky mucus in the lungs of patients with CF. This mucus fosters chronic infection and inflammation, and results in irreversible lung damage. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets CFTR SARS-CoV-2 Molecular Formula C24H18F2N2O5 Molecular Weight 452.41 Ordering Information Catalo g Numbe r Siz e Pric e Stoc k Quantity B0084- 079818 250 mg $188In stock 0 Bulk Inquiry Add to cart Chemical Information

2. Category Inhibitor Molecular Formula C24H18F2N2O5 Molecular Weight 452.41 Specification Properties Reference Reading    Purity ≥98% Synonyms VX-809; VX809; VX 809; VRT 826809; VRT826809; VRT-826809 Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT00865904Study of VX-809 in Cystic Fibrosis Subjects With the ∆ F508-CFTR Gene Mutation Cystic Fibrosis Phase 2 March 2009 Vertex Pharmaceuticals Incorporated Completed NCT00966602Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects Cystic Fibrosis Phase 1 September 2009 Vertex Pharmaceuticals Incorporated Completed NCT01216046Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects Cystic Fibrosis Phase 1 October 2010 Vertex Pharmaceuticals Incorporated Completed NCT01225211Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation Cystic Fibrosis Phase 2 October 2010 Vertex Pharmaceuticals Incorporated Completed

3. NCT01768663A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects Cystic Fibrosis Phase 1 January 2013 Vertex Pharmaceuticals Incorporated Completed Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 2.2104 mL 11.0519 mL 22.1038 mL 5 mM 0.4421 mL 2.2104 mL 4.4208 mL 10 mM 0.2210 mL 1.1052 mL 2.2104 mL 50 mM 0.0442 mL 0.2210 mL 0.4421 mL https://www.bocsci.com/lumacaftor-cas-936727-05-8-item-79818.html